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Abstract
Background: In 2014, almost half of the global tuberculosis deaths occurred in the World Health Organization
(WHO) African Region. Approximately 21.5 % of the 6 060 742 TB cases (new and relapse) reported to the WHO in
2014 were in the African Region. The specific objective of this study was to estimate future gross domestic product
(GDP) losses associated with TB deaths in the African Region for use in advocating for better strategies to prevent
and control tuberculosis.
Methods: The cost-of-illness method was used to estimate non-health GDP losses associated with TB deaths.
Future non-health GDP losses were discounted at 3 %. The analysis was conducted for three income groups of
countries. One-way sensitivity analysis at 5 and 10 % discount rates was undertaken to assess the impact on the
expected non-health GDP loss.
Results: The 0.753 million tuberculosis deaths that occurred in the African Region in 2014 would be expected to
decrease the future non-health GDP by International Dollars (Int$) 50.4 billion. Nearly 40.8, 46.7 and 12.5 % of that
loss would come from high and upper-middle- countries or lower-middle- and low-income countries, respectively.
The average total non-health GDP loss would be Int$66 872 per tuberculosis death. The average non-health GDP
loss per TB death was Int$167 592 for Group 1, Int$69 808 for Group 2 and Int$21 513 for Group 3.
Conclusion: Tuberculosis exerts a sizeable economic burden on the economies of the WHO AFR countries. This
implies the need to strongly advocate for better strategies to prevent and control tuberculosis and to help
countries end the epidemic of tuberculosis by 2030, as envisioned in the United Nations General Assembly
resolution on Sustainable Development Goals (SDGs).
Multilingual abstracts
Please see Additional file 1 for translations of the ab-
stract into the six official working languages of the
United Nations.
Background
The World Health Organization (WHO) estimates that
the total number of deaths from tuberculosis (TB)
worldwide was 1.514 million in 2014 [1]. Almost half of
those deaths were from the WHO African Region. Ap-
proximately 21.5 % of the 6 060 742 TB cases (new and
relapse) reported to the WHO in 2014 were in the
African Region [1].
According to the WHO, TB is intimately linked to
poverty, and the control of TB is ultimately a question
of justice and human rights [2]. Failure to control TB
(and other poverty-related diseases) is a consequence of
the significant inequities in the distribution of wealth
and health care both within and between countries [3–
6]. In the African Region, the situation is exacerbated by
the relatively high incidence and prevalence of co-
infection of HIV/AIDS and TB and the growing problem
of mycobacterial drug resistance [7–10].
The majority of TB deaths could have been prevented
if the available preventive and treatment interventions
were universally accessible to all those in need. Unfortu-
nately, the coverage of those interventions is suboptimal
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in the African Region. For example, the BCG (Bacillus
Calmette–Guérin) immunisation coverage among infants
(aged 1 year) is between 50 and 70 % in 4 countries, 71–
90 % in 17 countries, and 91 % and above in 26 coun-
tries [11]. The case detection rate for all forms of TB
was 52 %, and the treatment success rate for new tuber-
culosis cases was 81 % [12]. In the absence of an effect-
ive vaccine for older ages, efforts to control the spread
of TB will continue to rely on early diagnosis, directly
observed therapy (DOTs) and public health infection
control measures.
The prevention and control of TB is hampered by
poor living conditions for vulnerable population groups
and weak national health systems [12]. The national
health systems lack capacities to assure universal access
to TB prevention and control services for all those in
need [13–16].
The situation calls for strong evidence-based advocacy
for increased domestic and external investments into the
fight against TB. One such evidence is the economic
burden of TB. A retrospective cost-of-illness study in
the United States estimated the 1991 direct expenditures
for TB-related diagnosis and treatment to range from
$515.7 million to $934.5 million [17]. Miller et al. esti-
mated that in 2002, the 108 confirmed TB cases in
Tarrant County (Texas, USA) cost a total of US$40 574
953 [18]. Rajbhandary et al. estimated the mean direct
cost of treating a multi-drug-resistant (MDR-TB) patient
in the United States to be US$45,000 [19].
Atun et al. estimated the mean cost of managing TB
in Russia over 12 months to be US$572 per case [20].
Fløe et al. estimated the direct cost per TB patient to be
€10 509 in Denmark [21]. Kik et al. estimated the direct
and indirect costs of tuberculosis among immigrant pa-
tients in the Netherlands to be Euro 2 956 per TB pa-
tient [22]. The Diel et al. study in Germany estimated
the total cost per MDR-TB/extensively drug-resistant
(XDR-TB) case to be Euro 82 150 and Euro 108 733 per
case, respectively [23]. In another study, Diel and col-
leagues performed a systematic review and revealed that
the average cost of treatment of MDR-TB among 15 old
European Union (EU countries plus Cyprus, Malta and
Slovenia to be Euro 57 213 and Euro 24 166 [24]. White
and Moore-Gillon estimated the mean direct cost of
managing an MDR-TB patient in the United Kingdom
to be £60 000 [25].
The Rajeswari et al. study in India estimated the total
socio-economic impact of tuberculosis on patients and
their families to be US$171 per case [26]. The Peabody
et al. study in the Philippines estimated the combined
economic losses due to premature tuberculosis-related
mortality and morbidity to be US$145 million [27]. The
Atif et al. study in Malaysia estimated the cost of tuber-
culosis treatment to be US$ 727.25 per patient [28].
The Mauch et al. study in Kenya revealed that a TB
patient incurred a median direct cost of US$55.8 and an
indirect cost of US$294.2 [29]. The Umar et al. study in
Nigeria estimated the indirect cost due to pulmonary TB
in patients receiving treatment to be US$517.98 and
US$79.13 per hospitalised and non-hospitalized patient,
respectively [30]. The Foster et al. study in South Africa
estimated the mean total pre-treatment and treatment
direct plus indirect costs incurred by respondents in
accessing health care during TB diagnosis and treatment
to be US$ 324.07 [31].
Except for Peabody et al. [27], none of the other studies
included the economic losses due to premature
tuberculosis-related mortality. In addition, to the best of
our knowledge, no study has attempted to estimate the
combined economic losses due to premature tuberculosis-
related mortality for all 47 countries of the WHO African
Region. Therefore, there is a dearth of evidence in the
African Region on the economic burden of TB for use in
advocacy for increased domestic and external investments
in strengthening the national and local health systems to
combat the spread of TB.
This paper attempts to answer the following question:
What is the impact of TB deaths on the future non-
health gross domestic product (GDP) in the WHO
African Region? The specific objective of this study was
to estimate the future GDP losses associated with TB
deaths in the African Region to advocate for better strat-
egies to prevent and control tuberculosis.
Methods
Cost-of-illness framework
Tuberculosis deaths result in future losses in the macro-
economic outputs of countries concerned with attrition
of future labour and productivity, as well as an erosion
of investments in human and physical capital formation
[32]. In this paper, we employ a cost-of-illness model to
estimate the non-health GDP losses attributable to TB-
related deaths in the African Region.
Nattrass et al. [33] defines GDP as the value of the ag-
gregate spending on all final goods and services. GDP is
the sum of the private household consumption spending
on final consumer goods (e.g., food, cloth, books, deter-
gents) and services (e.g., health, education, tourism);
central, regional and local government consumption
spending on salaries and wages of civil servants and
goods; private and public sectors producers investment
spending on additional physical stock of capital (e.g.,
machinery, construction, vehicles) plus changes in the
total value of inventories (unsold stocks); and net ex-
ports (i.e., exports minus imports).
Private consumption is the use of goods and services
to directly satisfy an individual’s personal needs and
wants [33]. Private consumption spending is funded
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from incomes earned by employees and self-employed
people (e.g., farmers, entrepreneurs) and thus premature
death of workers or self-employed people from tubercu-
losis (or any other cause) depletes household income
and consumption. Death of those aged 0–14 years di-
minishes the quantity of future labour force and hence
future household income and consumption.
Government consumption spending is financed largely
through revenues from various forms of taxes, such as
personal income tax, value-added tax, social security
taxes, corporate taxes, and taxes on international trade
and transactions [34]. Premature mortality due to tuber-
culosis (or any other cause) reduces the number of
current and future tax payers and hence tax revenues
available for government consumption spending and
investment.
Investment spending is financed by savings, i.e., loan-
able funds [33, 34]. Once again, premature death from
TB erodes a household’s current and future income and
savings needed by investors. At times, the bereaved are
forced by circumstances to sell assets and spend savings
to pay for funeral expenses.
Agriculture is the main source of income and employ-
ment for the 62 % of the African Region population that
lives in rural areas. In 2013, agriculture (including crops,
forestry, hunting, and fishing, and livestock production)
contributed 14.7 % to the GDP of Sub-Saharan Africa.
However, the contribution varies from 2.3 % in South
Africa to 58.2 % in the Central African Republic. Of 41
countries reporting, agriculture contributed to less than
10 % in 12 countries; 10–30 % in 16 countries; and 31–
60 % in 13 countries [35]. Premature TB deaths would
be expected to impact negatively on the agricultural and
other sectors productivity.
According to WHO [32], the key ways through which
tuberculosis deaths impact macroeconomic output in-
clude increased health expenditure, losses in labour and
productivity and reduced investment in human and
physical capital formation. This study uses a macroeco-
nomic—or societal—perspective. The study’s scope is
limited to market economy losses (GDP), its quantity of
interest is the impact of tuberculosis deaths on non-
health components of GDP, and its estimation method is
the cost-of-illness model capturing the effects across all
sectors of the economy [36].
The non-health GDP loss (NHGDPLoss) associated
with tuberculosis deaths in a country is the sum of
the potential non-health GDP loss due to tuberculosis
deaths among those aged 0–14 (NHGDPLoss0 − 14),
those aged 15–59 (NHGDPLoss15 − 59) and those aged
60 years and above (NHGDPLoss60 ±). Economic losses
among the three age brackets were estimated to facili-
tate comparisons and to avail information for use in
advocacy for an increase in investments against
tuberculosis, and the growing challenge of antimicro-
bial resistance in the region.
The non-health GDP loss associated with tuberculosis
deaths among persons of a specific age group is the
product of the total discounted years of life lost, per
capita non-health GDP in purchasing power parity (PPP)
and the total number of tuberculosis deaths. Each coun-
try’s discounted total non-health GDP loss attributable
to tuberculosis deaths was estimated using eqs. (1), (2),
(3) and (4) presented below [37].
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where 1/(1 + r)t is the discount factor; r is the rate of dis-
count of future losses;
Xn
t¼1
is the summation from year t
to n; t is the first year of life lost, and n is the final year
of the total number of years of life lost per tuberculosis
death, which is obtained by subtracting the average age at
death (AAD) for tuberculosis-related causes from each
country’s average life expectancy at birth. NHGDPPC Int$
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is the per capita non-health gross domestic product in
purchasing power parity (PPP), which is obtained by sub-
tracting the per capita total health expenditure (PCTHE)
from the per capita GDP (GDPPC Int$). TBD0 − 14 is the
total tuberculosis deaths between the ages of 0–14 years
in country k in 2013; TBD15 − 59 is the total tuberculosis
deaths between the age of 15–59 years in country k in
2013; and TBD60 ± is the total tuberculosis deaths for ages
60 years and above in country k in 2013. We used 2013 as
the base year to which losses occurring in future years
were discounted. As explained by Kirigia [38], Drummond
et al. [39] and Curry and Weiss [40], the discount factor
applied to the GDP losses of different years then depends
on both the discount rate (r) and the number of years (t)
over which the discounting is conducted.
The non-health GDP per capita in purchasing power
parity for each of the 47 countries in the WHO African
Region was calculated by subtracting the per capita total
health expenditure from the per capita GDP.
Illustration of calculation of loss in total non-health GDP
The example below presents a calculation of the tuber-
culosis death-related loss in non-health GDP using the
actual information on Nigeria:
(a)Total tuberculosis deaths in Nigeria in 2014 = 250 000
(b)Proportion of deaths among those aged 0–14 years
= 0.125255548607164
(c)Proportion of deaths among those aged 15–59 years
= 0.774170807391794
(d)Proportion of deaths among those aged 60+ years =
0.100573644001042
(e)TBD0 − 14 = 250000 × 0.125255548607164 =
31313.887151791
(f )TMD15 − 59 = 250000 × 0.774170807391794 =
193542.701847949
(g)TMD60 + = 250000 × 0.100573644001042 =
25143.4110002605
(h)Average age at death among those aged 0–14 years
(AAD0 − 14), i.e., (0 + 14)/2 = 7 years
(i) Number of years needed, in addition to AAD0 − 14, to
reach the legal minimum age for employment of
15 years (Age0 − 14Min), i.e., 7 years.
(j) Average age at death among those aged 15–59 years
(AAD15 − 59), i.e., (15 + 59)/2 = 37 years
(k)Average age at death among those aged 60 years and
older (AAD60 ±), i.e., 60 years
(l) Nigeria’s average life expectancy at birth (LE) = 55 years
(m)Per capita gross domestic product (GDPPC Int$ ) =
Int$5756.271
(n)Per capita total expenditure on health (PCTHE) =
Int$207
(o)NHGDPPC =GDPPC Int$ − PCTHE = Int$ 5756.271 −
Int$207 = Int$ 5550
(p)Discount rate (r) = 3 %
(q)Undiscounted years of life lost in the group aged
0–14 years (YLL0 − 14) = LE – (AAD0 − 14 +Age0 −
14Min ) = 55 – (7 + 7) = 41 years
(r) Discounted years of life lost in the group aged 0–14
years (DYLL0 − 14) = 23.4123999749577
(s) Undiscounted years of life lost in the group aged
15–59 years (YLL15 − 59) = LE −AAD15 − 59 =
55 – 37 = 18 years
(t) Discounted years of life lost in the group aged 15–59
years (DYLL15 − 59) = 13.7535130794572
(u)Undiscounted years of life lost in the group aged 60
+ years (YLL660 ±) = LE −AAD60 ± = 0 (because the
Nigeria average LE of 55 years is less than 60 years,
we assumed that years of life lost within this age
group are zero. However, this assumption is adjusted
in the sensitivity analysis where we re-estimate the
model using highest life expectancy in the region,
i.e., 75 years in Cape Verde).
(v)Discounted years of life lost in the group aged 60+
years (DYLL60 +) equals zero for reason explained in
‘t’ above.
(w)NHGDPLoss0 − 14 = Discounted YLL0 − 15 ×
NHGDPPC Int$ × TBD0 − 14 = 23.4123999749577 ×
5550 × 31313.887151791 = Int$4 068 889 541.76473
(x)NHGDPLoss15 − 59 = Discounted YLL15 − 59 ×
NHGDPPC Int$ × TBD15 − 59 = 13.7535130794572 ×
5550 × 193542.701847949 = Int$14 773 501 051.2108
(y)NHGDPLoss60 ± = Discounted YLL60 ± ×NHGDPPC
Int$ × TBD60 ± = 0 × 5550 × 25143.4110002605 = Int$0.
(z)NHGDPLoss = (NHGDPLoss0 − 14 +NHGDPLoss15 −
59 +NHGDPLoss60 ±) = Int$4 068 889 541.76473 +
Int$14 773 501 051.2108 + Int$0 = Int$18 842
390 592.9755.
Sensitivity analysis
A discount rate of 3 % was used because it is commonly
used in cost-of-illness studies [41, 42], burden of disease
studies [43, 44] and WHO health systems’ performance
assessment [45]. However, a one-way sensitivity analysis
was conducted at 5 and 10 % discount rates to test the
effect of the discount rate on the overall total expected
non-health GDP loss estimate.
The study used 7 years (a simple average) as the aver-
age age at death for the 0–14 age bracket; 37 years for
the 15–59 age bracket; and 60 years for the 60 years and
above. Because the legal minimum working age limit is
15 years [46], we considered only the years above
14 years when calculating the productive years of life
lost for the 0–14 age bracket. A sensitivity analysis was
conducted to determine the effect of age on the overall
total non-health GDP loss estimate. The model was re-
estimated assuming an average age at death of 0 years
for the 0–14 age bracket; an average age at death of
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15 years for the 15–59 age bracket; and each country’s
average life expectancy as the average age at death for
the age bracket of 60 years and above, while simultan-
eously assuming the African Region’s maximum life ex-
pectancy of 75 years (i.e., life expectancy for Cape
Verde).
Data sources and analysis
The data used to estimate eqs. 1, 2, 3 and 4 were ob-
tained from following sources: the life expectancy at
birth data were taken from WHO World Health Statis-
tics 2015 [12]; the proportions of deaths occurring in the
three age groups were from the WHO mortality and
burden of disease estimates for WHO member states in
2008 [43]; the total tuberculosis deaths were taken from
the WHO World Tuberculosis Report 2015 [1]; the per
capita gross domestic product in purchasing power par-
ity (PPP) values were from the International Monetary
Fund database [47]; and per capita total health expend-
iture data were from the World Health Statistics 2015
[12].
The formulas in eqs. (1), (2), (3) and (4) were used to
estimate the non-health GDP losses and were built in an
Excel spreadsheet. For the analysis, the countries were
organised into three economic groups, as shown in
Table 1, with high- and upper-middle-income countries
in Group 1, lower-middle-income countries in Group 2
and low-income countries in Group 3. A calculation for
the countries by income group was meant to facilitate
comparisons.
Ethical clearance
The study did not require WHO/AFRO Ethics Review
Committee approval because it did not involve human
subjects. It relied entirely on data from published
sources.
Results
Table 2 presents the WHO African Region’s population
and tuberculosis deaths by economic group in 2014. Of
the total of 753 423 tuberculosis deaths that occurred,
16.26 % belonged to the high- and upper-middle-income
countries (Group 1), 44.73 % to the lower-middle-
income countries (Group 2) and 39.01 % to the low-
income countries (Group 1).
Non-health GDP loss attributable to tuberculosis deaths
The 0.753 million tuberculosis deaths that occurred in
the African Region in 2014 would be expected to de-
crease future non-health GDP by Int$50,382,574,953
(Table 3). Nearly 40.8 % of the loss would be represented
by Group 1 countries, 46.7 % by group 2 and 12.5 % by
group 3. The interquartile range of the median GDP loss
by country is Int$440,387,653. The potential loss of fu-
ture discounted non-health GDP would vary widely,
from Int$0 in Seychelles to Int$18.84 billion in Nigeria.
Non-health GDP loss in Group 1 countries
The 122 526 TB deaths in Group 1 countries are ex-
pected to result in a total loss of Int$20 534 328 490 in
non-health GDP in 2013, which is equivalent to 1.36 %
of the group’s total GDP. The total productivity loss var-
ied importantly, from Int$0 in Seychelles to Int$16.6 bil-
lion in South Africa. Figure 1 displays the distribution of
the total non-health GDP across the nine high and
upper-middle income countries in Group 1. Approxi-
mately 81 % of the expected loss in Group 1 was repre-
sented by South Africa.
Table 1 Economic classification of WHO African Region Countries in 2013
Group GNI per capita (US$) Countries
Group 1: High income and upper-middle income > = 4 086 Algeria, Angola, Botswana, Equatorial Guinea, Gabon, Mauritius, Namibia,
Seychelles, South Africa (9)
Group 2: Lower-middle income 1 036–4 085 Cameroon, Cape Verde, Congo, Cote d’Ivoire, Ghana, Kenya, Lesotho,
Mauritania, Nigeria, São Tome and Principe, Senegal, Swaziland, Zambia (13)
Group 3: Low income 1 035 or less Benin, Burkina Faso, Burundi, Central African Republic, Chad, Comoros,
DRC, Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Liberia,
Madagascar, Malawi, Mali, Mozambique, Niger, Rwanda, Sierra Leone,
South Sudan, Tanzania, Togo, Uganda, Zimbabwe (25)
Table 2 Population and tuberculosis deaths by economic group in WHO African Region countries
Group/economic class (A) Population in 2013 (B) Tuberculosis Deaths in 2014 Percentage = (B/A)x100
Group 1: High income & upper-middle income 121 546 000 122 526 0.101
Group 2: Lower-middle income 331 470 000 337 009 0.102
Group 3: Low income 478 356 000 293 888 0.061
TOTAL 931 372 000 753 423 0.081
Source: WHO [1, 12]
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Non-health GDP loss in Group 2 countries
The 337 009 TB deaths in Group 2 countries resulted in
an expected total loss of Int$23 525 835 936 in non-
health GDP, or 1.6 % of the group’s total GDP. The loss
was wide-ranging, from Int$1 007 272 in São Tomé and
Príncipe to Int$18 841 273 630 in Nigeria. Figure 2 pre-
sents the distribution of the total non-health GDP loss
across the 13 lower-middle income countries in Group
2. Approximately 80.1 % of the loss in Group 2 was rep-
resented by Nigeria.
Non-health GDP loss in Group 3 countries
The 293 888 TB deaths that occurred among Group
3 countries in 2013 resulted in a total expected loss
in non-health GDP of Int$6 322 410 528, which is
equivalent to 0.91 % of the group’s total GDP. The
expected loss varied from Int$1.5 million in Comoros
to Int$2.54 billion in Tanzania. Figure 3 shows the
distribution of the total non-health GDP loss across
the 25 low-income countries in Group 3. The Demo-
cratic Republic of the Congo (DRC), Ethiopia,
Madagascar, Mozambique and Tanzania collectively
incurred 76.8 % of the expected loss in this group. In
spite of the fact that Group 3 TB deaths were 2.4
times those of Group 1, the non-health GDP loss of
Group 1 was 3.2 times higher than that of Group 3
because Group 1 had a higher per capita GDP.
Average non-health GDP losses
Table 4 shows the average non-health GDP losses per
TB death and per person in population for the 47 coun-
tries. The average non-health GDP lost per TB death
was Int$167,592 for Group 1, Int$69 808 for Group 2
and Int$21,513 for Group 3. The average non-health
GDP loss per person in the population was Int$168.9 for
Group 1, Int$71 for group 2 and Int$13.2 for Group 3.
The average non-health GDP lost per TB death was
slightly more than two times that for Group 2 and about
eight times that for Group 3.
Sensitivity analysis
Employing a 5 % discount rate reduced the total ex-
pected non-health GDP loss by Int$9.703 billion
Table 3 Discounted values of future non-health GDP losses
from tuberculosis deaths among WHO African Region countries
in 2014 (2013, Int$ or PPP)
Countries International Dollars (PPP) Percentage
Algeria 1 245 265 365 2.47
Angola 1 283 658 670 2.55
Benin 36 750 328 0.07
Botswana 405 550 047 0.80
Burkina Faso 52 205 284 0.10
Burundi 42 896 468 0.09
Cameroon 671 947 468 1.33
Cape Verde 23 398 102 0.05
Central African Republic 36 287 667 0.07
Chad 160 379 659 0.32
Comoros 1 492 351 0.00
Congo 432 543 715 0.86
Cote D’Ivoire 229 438 028 0.46
DRC 426 514 828 0.85
Equatorial Guinea 64 069 641 0.13
Eritrea 18 720 135 0.04
Ethiopia 870 327 842 1.73
Gabon 392 992 668 0.78
Gambia 12 332 470 0.02
Ghana 934 667 549 1.86
Guinea 87 848 382 0.17
Guinea-Bissau 44 826 660 0.09
Kenya 870 294 829 1.73
Lesotho 149 807 038 0.30
Liberia 43 220 969 0.09
Madagascar 301 036 739 0.60
Malawi 140 425 230 0.28
Mali 44 430 032 0.09
Mauritania 61 852 822 0.12
Mauritius 8 191 726 0.02
Mozambique 719 984 725 1.43
Namibia 501 033 284 0.99
Niger 54 836 009 0.11
Nigeria 18 841 273 630 37.40
Rwanda 25 108 682 0.05
Sao Tome & Principe 1 007 272 0.00
Senegal 131 075 954 0.26
Seychelles – 0.00
Sierra Leone 46 928 838 0.09
South Africa 16 633 567 089 33.01
South Sudan 119 338 372 0.24
Swaziland 233 669 870 0.46
Table 3 Discounted values of future non-health GDP losses
from tuberculosis deaths among WHO African Region countries
in 2014 (2013, Int$ or PPP) (Continued)
Tanzania 2 538 873 431 5.04
Togo 17 528 131 0.03
Uganda 289 994 353 0.58
Zambia 944 859 661 1.88
Zimbabwe 190 122 940 0.38
Total loss (Int$) 50 382 574 953 100.00
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(19.26 %) and the average non-health cost per TB death
by Int$12 878. Whereas, application of a 10 % discount
rate reduced the overall total non-health GDP loss by
Int$23 851 884 140 (47.34 %) and the average non-
health GDP loss per TB death by Int$31 658.
The use of the average age at death of 0 years for the
0–14 age bracket; 15 years for the 15–59 age bracket;
and each country’s average life expectancy as the average
age at death for the age bracket of 60 years and above,
while simultaneously assuming the region’s maximum
life expectancy of 75 years, raised the total non-health
GDP loss by Int$28.4 billion, which is a 56.3 % increase.
This also increased the average non-health GDP loss per
TB deaths by Int$37,649. Because the non-health
GDP loss also seems to partially depend on the aver-
age age used for the onset of TB deaths, there is a
need for epidemiological research into the age distri-
bution of TB deaths.
Discussion
The estimated total expected non-health GDP loss as-
cribed to TB deaths of Int$50.4 billion is approximately
1.37 % of the collective GDP of the 47 WHO African
Region member states. This estimate signifies the ex-
pected loss in potential GDP in the future from the
753,423 TB deaths, which is revalued relative to the base
year of 2013. The sensitivity analysis revealed that the
size of the total non-health GDP loss partially depends
on the discount rate used and the average age used for
the onset of TB deaths. The latter implies that there is a
need for epidemiological research into the age distribu-
tion of TB deaths.
The Group 3 (low income) countries are the home of
51.4 % of the African Region population, incurred 39 %
of TB deaths, and bore only 12.5 % of non-health GDP
losses associated with TB deaths in the region. On the
other hand, even though Group 1 (high income and
upper-middle income) countries have only 13.1 % of the
regional population and incurred only 16.3 % of TB
deaths (probably due to better living and working condi-
tions), it bore 40.8 % of the non-health GDP losses asso-
ciated with TB in the region. This is attributed to the
fact that the Group 1 per capita income of Int$9,257 is
eight times higher than that of Group 3 countries of
Int$1,131. This implies that even though the TB disease
burden is lower in Group 1 vis-a-vis Group 3, it should
not be a reason for complacency because the negative
impact on Group 1 economies is quite sizeable.
As mentioned in the Background, there is a worldwide
paucity of studies that estimate the economic losses due
to premature mortality from TB. Peabody et al. estimated
the combined annual income loss due to TB morbidity
and premature mortality to be US$145 million in the
Philippines in 1997, of which US$32 million (22.1 %) was
Fig. 1 Non-health GDP loss in Group 1 due to tuberculosis deaths in high-income and upper-middle- income countries of the WHO African
Region, 2013
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attributed to premature mortality [27]. Hickson estimated
the magnitude of the decline in the mortality and morbid-
ity burden of TB at 104,425 life years, valued at US$127
billion in England and Wales. Out of the latter loss, $71
billion (55.9 %) was attributed to TB mortality [48]. The
median GDP loss per country in the African Region was
Int$140.4 million in 2013, which confirms that premature
mortality from TB lowers a country’s GDP.
Cognizant of the correlation between health and eco-
nomic development, the UN General Assembly in 2015
adopted a development agenda whose sustainable devel-
opment goal (SDG) 3 focuses on ensuring healthy lives
and promoting well-being for all people at all ages [49].
Target 3.3 focuses on ending the epidemics of AIDS, tu-
berculosis, malaria and neglected tropical diseases and
combating hepatitis, water-borne diseases and other
communicable diseases by 2030. The Sixty-Seventh
World Health Assembly resolution, WHA67.1, adopted
the global strategy and targets for TB prevention, care
and control after 2015 [50]. The strategy provides de-
tailed guidance to member states on key interventions
for eliminating TB by 2035; some of which include the
following: early diagnosis and treatment using DOTS;
treatment of all people with multi-drug-resistant TB;
and antiretroviral therapy for HIV-positive TB patients
with tuberculosis/HIV activities [51].
One may ask whether those interventions are econom-
ically viable. Korenromp et al. [52] projected that in the
African Region, the cost of diagnosing and treating one
TB patient under DOTS would be US$503, with an add-
itional cost incurred if the patient has multi-drug resist-
ance (MDR) TB that would be US $4 315. Other
additional costs would be incurred if the patent is HIV-
positive and receives antiretroviral therapy (ART) for the
duration of a 6-month DOTS course, which would be
US$236 in 2010. As shown in Table 5, if we inflate those
Fig. 2 Non-health GDP loss in Group 2 due to due to tuberculosis deaths in lower-middle-income countries of the WHO African Region, 2013
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2010 costs by 3 % per year over a period of 3 years (to
2013) and sum them, then we obtain a total cost of
US$1 975 738 381, which when discounted at 3 % comes
to $1 918 192 602. Dividing the GDP loss (which is po-
tential savings) of $50.4 billion by the cost of TB
interventions ($1.92 billion) yields a benefit-cost ratio
(BCR) of 26.2. This means that policymakers can expect
$26.2 in benefits for every $1 invested in the three TB
interventions. Therefore, since the BCR is greater than
1, this means the benefits outweigh the costs and the
Fig. 3 Non-health GDP loss in Group 3 due to tuberculosis deaths in low-income countries of the WHO African Region, 2013
Table 4 Discounted values of future non-health GDP lost due to TB deaths in 2014 by economic group (in 2013 international
dollars)
Cost item Group 1 (Int$) Group 2 (Int$) Group 3 (Int$) Grand total Cost (Int$)
Total cost of TB deaths 20 534 328 490 23 525 835 936 6 322 410 528 50 382 574 953
Average cost per TB death 167 592 69 808 21 513 66 872
Average cost per person in population 168.9 71.0 13.2 54.1
% of Grand Total 40.8 46.7 12.5 100
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investment into the three interventions for TB patients
should be considered worthwhile.
The sizeable economic losses attributable to prema-
ture TB-related mortality imply an urgent need for gov-
ernments (in collaboration with the Regional Economic
Communities, the private sector, the civil society, Glo-
bal Health Initiatives and development partners) to
fully implement the global End TB Strategy to eliminate
premature mortality from TB. The full implementation
of the strategy to curb the TB disease burden and at-
tenuate the related economic losses has high-level
political support contained in the decisions and reso-
lutions on TB from the Organization of African
Unity/African Union [53–56], the WHO Regional
Committee for Africa [57–60], the World Health As-
sembly [50, 61–64] and the United Nations General
Assembly [65, 66].
Limitations of the study
This study has a number of limitations. First, it fo-
cuses only on the effects that TB-related premature
mortality has on the economy. It does not include
the cost of absence from work and reduced labour
performance/productivity due to prolonged periods
of sickness. We omitted direct costs, including
health care cost of treating ordinary TB cases and
those resulting from longer hospital stays for indi-
viduals with resistant infections, e.g., MDR-TB and
XDR-TB.
Second, the GDP per capita gives no indication about
how available resources are distributed across people
and households. For instance, the average income per
capita might remain unchanged while the distribution of
income changes, which has implications for the typical
household [67].
Third, the GDP only captures economic activities associ-
ated with market transactions. Its calculation omits the value
of full-time homemakers (domestic labour). For example,
the value of labour of women who choose to stay at home
doing house work and raising children is omitted [68].
Fourth, GDP does not include the cost of production
or consumption processes externalities such as pollution,
environmental degradation and costs of substance abuse
(e.g., alcohol, smoking) [68].
Finally, loss of human life due to tuberculosis has an
effect on the well-being of the bereaved family members
that goes well beyond the loss of incomes to which it
gives rise [69]. Some of that effect includes psychological
pain of losing a loved one; the stress and anxiety of los-
ing a caretaker or a breadwinner; and negative impact
on the children’s nutrition status and education when a
parent dies.
Conclusion
This paper sought to contribute to the literature on the
economic burden of TB. The 47 WHO African Region
Member States lost 1.37 % of their combined GDP due
to the 753 423 TB deaths in 2014. That is a sizeable loss
in a Region where 47 % of the population lives on less
than one international dollar per day [12]. Approxi-
mately 75.86 % of the loss was represented by those aged
15–59 years, which is the most productive age bracket.
The fact that a premature mortality resulting from TB
lowers the GDP implies that the governments of African
countries in collaboration with the Regional Economic
Communities, private sector, the civil society, Global
Health Initiatives and development partners ought to
support full implementation of the Global End TB
Strategy.
The economic evidence contained in this paper is only
one argument for the universal coverage of public health
interventions to end morbidity and premature mortality
from TB. The literature is replete with other arguments
such as the contagious nature of TB and its threat to glo-
bal health security [70], the growing burden of MDR-TB
and XDR-TB [1, 71], comorbidity of HIV and TB [72],
sub-optimal performance of national TB programmes [73]
and human rights (social justice) considerations [74].
Additional file
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Table 5 Total cost of TB interventions and the benefit-cost ratio for the African Region
Variables Number of TB casesa Cost per TB patient ($)b Sub-Total Cost ($)
TB Incidence (including HIV) 2 700 000 549.6417 1 484 032 538.70
TB Incidence (HIV-positive) 870 000 257.8836 224 358 707.64
MDR-TB 56 700.00 4715.117 267 347 134.18
Undiscounted total cost (USD) 1 975 738 381
(A). Discounted total cost (Int$) at a 3 % rate 1 918 192 602.45
(B). GDP Loss (potential saving) 50 382 574 953
Benefit/cost ratio, i.e., (B)/(A) 26.2656497
Source: aWHO [1]; bKorenromp et al. [52]
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